Lung Cancer

Lung cancer is the leading cause of cancer death in the United States and around the world. Almost as many Americans die of lung cancer every year as die of prostate, breast, and colon cancer combined.

Lung cancer tumors are divided into two broad histological categories: non-small cell lung carcinoma (NSCLC) and small-cell lung carcinoma (SCLC). NSCLC represents more than 80 to 85% of lung cancers of which approximately 40% are adenocarcinoma, 25 to 30% are squamous cell carcinoma, and 10 to 15% are large cell carcinomas.
Survival rates are grouped based on the stage, but additional factors, including cell type (NSCLC vs. SCLC), the presence of actionable mutations, age, and comorbidities can also affect treatment outlook. The 5-year relative survival rate for lung cancer is 19.4% (16% for men and 22% for women) and is higher for NSCLC (23%) than for SCLC (6%).  The low survival rate reflects the fact that the majority of patients with lung cancer are diagnosed with advanced stages of disease. However, local therapy for early stage disease is associated with substantially improved overall survival.

Since 2011 evidence has been accumulated in favour of lung cancer screening trough low-dose helical computed tomography (LDCT). The introduction of a screening strategy is associated with a favorable stage shift from advanced to more early stage lung cancers.
The geographic and temporal patterns of lung cancer incidence, as well as lung cancer mortality, on a population level are mainly determined by tobacco consumption, the main aetiological factor in lung carcinogenesis. Other factors such as genetic susceptibility, poor diet, occupational exposures and air pollution may act independently or in concert with tobacco smoking in the pathofisiology of lung cancer.

Most patients will require multidisciplinary input over the course of their diagnosis and treatment. Development of multidisciplinary programs supported by members of the major disciplines involved in lung cancer care, namely the pulmonologist, thoracic surgeon, chest radiologist, pathologyst and the medical and radiation oncologists, is pivotal to ensure patients optimal treatment.
Major advances in lung cancer therapeutics include minimally invasive surgical techniques, refinements in radiotherapy, and a burgeoning of new systemic therapies targeting molecular pathways and the immune system.

Lung Cancer Studies


Lung Cancer Studies


There are several studies available, here are some of the ones you can find:

Status Study Conditions Interventions Locations
Recruiting Second Primary Lung Cancer Cohort Study (SPORT) Lung Cancer Royal Papworth Hospital
Cambridge, United Kingdom
Recruiting Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung Cancer Lung Cancer Drug: Niraparib
Drug: Osimertinib
  • Dana Farber Cancer Institute
    Boston, Massachusetts, United States;
    Massachusetts General Hospital Cancer Center
    Boston, Massachusetts, United States;
    Beth Israel Deaconess
    Boston, Massachusetts, United States
Recruiting Prospective Epidemiological Study of Metastatic Non Small Cell Lung Cancer (NSCLC) in Latin America – LATINO Lung Lung Cancer
  • Centro Oncologico Riojano
    La Rioja, Rioja, Argentina;
  • Instituto De Oncologia De Rosario
    Santa Fe, Rosário, Argentina;
  • (and 25 more…)
Not yet recruiting DBT for Metastatic Lung Cancer Lung Cancer Metastatic Behavioral: Dialectical Behavioral Therapy Skills Training
Recruiting Early Detection of Lung Cancer in Czech High-risk Asymptomatic Individuals Lung Cancer Other: Response to pulmonary finding (nodule, mass) General University Hospital in Prague
Prague, Czechia
Recruiting A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer Lung Cancer
  • Drug: EGF816
    Drug: Gefitinib
Massachusetts General Hospital
Boston, Massachusetts, United States
Recruiting Stepped Palliative Care Versus Early Integrated Palliative Care in Patients With Advanced Lung Cancer Lung Cancer Other: Stepped PC
Other: Early Integrated PC
Massachusetts General Hospital
Boston, Massachusetts, United States;
Duke University
Durham, North Carolina, United States;
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Recruiting Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the MEK Inhibitor Binimetinib (MEK162) for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer Lung Cancer Drug: Binimetinib
Drug: Palbociclib
  • Dana Farber Cancer Institute
    Boston, Massachusetts, United States
    Massachusetts General Hospital
    Boston, Massachusetts, United States
Unknown Treatment Patterns in Advanced Small Cell Lung Cancer (SCLC) Lung Cancer
  • Other: Non-interventional
  • Local Institution
    Barcelona, Spain
Recruiting  Early Integrated Telehealth Versus In-Person Palliative Care for Patients With Lung Cancer Lung Cancer
  • Other: Telehealth
    Other: In-person PC
  • University of Alabama at Birmingham
    Birmingham, Alabama, United States;
  • City of Hope
    Los Angeles, California, United States;
  • (and 19 more…)

New Breathe


New Breathe




Call us now if you are in a medical emergency need, we will reply swiftly and provide you with a medical aid.

2021 © New Breathe. Powered with by Goweb Agency.

2021 © New Breath. Powered with by Goweb Agency.